23/07/2020

TELECHARGER

L’été est là pour rattraper le temps perdu, redécouvrez nos innovations scientifiques !

Retrouvez nos webinaires thématiques sur notre chaîne dédiée. Tous les webinaires sont en anglais.

Nos webinaires dévoilent l’ensemble de nos expertises au cours de la découverte de médicaments appliquées à l'oncologie et à l'inflammation. Oncodesign vous guide pour concevoir, optimiser et évaluer l'efficacité et le potentiel de développement de votre molécule, de la découverte de la cible jusqu’à l’IND.

Je deviens expert

7 Juillet 2020
17h CEST

Outsourcing drug discovery has become an overwhelmingly accepted approaches across the pharmaceutical industry from virtual biotech to large pharmaceutical companies as part of the globalization process. It does represent a cost-effective opportunity to access specialized technologies and expert scientist resources having a broad knowledge of pharmaceutical drug discovery development. Oncodesign’s objective with DRIVE™ offer is to provide its customers with the best possible options and state-of-the-art technologies to progress their drug discovery in the shortest possible time with the highest quality.

Oncodesign is doing so by setting up under a single leadership, privileged partnering with selected and trusted companies sharing the same values of innovation and quality as its own. 
Hits finding and validation are important phases in early drug discovery. With Program, Oncodesign is providing DNA encoded libraries, fragments screening along with Hit validation using NanoDSF, MST, SPR, ITC and Structural Biology (Cryo-EM and X-Ray crystallography) supported by artificial intelligence. 

Key learning Objectives

• Introduction to a solution provider from hits finding to IND filing
• Advantages of drug discovery integrated provider vs silos approach
• Special focus on Hit identification and validation across DNA encoded libraries, Artificial Intelligence, Biophsysics and Biostructures  

Discover our speakers

Voir la présentation en ligne

Samira Benhamouche-Trouillet, PhD, Senior Study Director
2 Juillet 2020
17h CEST

Liver pathologies account for significant burden of disease and costs, with more than 800 million people affected and a mortality rate of approximately 2 million deaths per year worldwide. Given the prevalence of obesity and diabetes mellitus worldwide, NAFLD will increasingly become the leading cause of chronic liver disease and hepatocellular carcinoma. For now, liver transplantation remains the only effective therapeutic option.

Acute liver injury is a syndrome of severe and abrupt hepatocyte injury and inflammation leading to liver failure. Many different etiologies have been identified, with acetaminophen (APAP) overdose and viral hepatitis being the most common causes. Chronic Liver diseases (CLD), irrespective of the etiology, are characterized by parenchymal injury, activation of inflammatory response, angiogenesis and sustained activation of liver fibrogenesis. Liver cirrhosis represent an advanced stage of CLD characterized by the formation of fibrotic septa surrounding regenerative nodules, changes in vascular architecture, portal hypertension and complications such as liver failure and hepatocellular carcinoma (HCC).

Providing palliative and curative solutions is an urgent necessity. At Oncodesign, we offer and develop both complementary and integrated strategies to mimic the different steps of liver diseases and cancer progression in mouse models, in order to develop novel therapies and elucidate the mechanisms of action. 

Key learning objectives

• Introduction to liver pathogeneses
• Models of acute liver injury
• Models of liver fibrosis and NASH
• Models of liver cancer

Discover our speaker Samira Benhamouche-Trouillet 

Samira Benhamouche-Trouillet is a study director at Oncodesign in the department of in vivo pharmacology.
She received her PhD in 2008 in biochemistry, cellular and molecular biology from Paris 11 University and Cochin institute (Paris, France) where she studied the role of Wnt/b-catenin signaling in liver homeostasis, regeneration and carcinogenesis. Then, for her postdoctoral training, she joined the Massachusetts General Hospital Cancer Center/ Harvard medical School (Boston, USA) from 2008 to 2013 to study the role of hepatic progenitor cells in cancer and mechanisms of biliary cells polarization and lumen formation during liver development. From 2013 to 2018, she was a group leader and assistant professor at Bordeaux University and Centre-Hepato-Biliaire (Paris area) where she worked on signal transduction pathways involved in lipid and glucose metabolism, NASH pathogenesis and in liver regeneration. In September 2018, she joined Oncodesign where she has been developing preclinical models for liver diseases and manages proof-of concept studies in inflammatory diseases and oncology.

Voir la présentation en ligne